Inhibition of evoked glutamate release by the neuroprotective 5-HT1A receptor agonist BAY x 3702 in vitro and in vivo

@article{Mauler2001InhibitionOE,
  title={Inhibition of evoked glutamate release by the neuroprotective 5-HT1A receptor agonist BAY x 3702 in vitro and in vivo},
  author={Frank Mauler and Thomas Fahrig and Ervin Horv{\'a}th and Reinhard Jork},
  journal={Brain Research},
  year={2001},
  volume={888},
  pages={150-157}
}

Figures from this paper

A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAYx3702) in ischemic stroke.
TLDR
The dose- and time-dependent neuroprotective efficacy of repinotan indicates that the drug is a promising candidate for prevention of secondary brain damage in brain-injured patients suffering from acute ischemic stroke, however, the first, randomized, double blind, placebo-controlled clinical trial did not demonstrate the efficacy of the drug.
Post-lesion administration of 5-HT1A receptor agonist 8-OH-DPAT protects cholinergic nucleus basalis neurons against NMDA excitotoxicity
TLDR
The results demonstrate that 8-OH-DPAT significantly attenuates both behavioral and neuroanatomical consequences of NMDA excitotoxicity on cholinergic MBN neurons, and support the hypothesis that 5-HT1A receptor agonists may interfere with delayed neuronal death in vivo that is of significance in the pharmacological treatment of neurological disorders associated withexcitotoxic neuronal damage.
Blockade of Striatal Adenosine A2A Receptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-Induced Excitotoxicity: Possible Relevance to Neuroprotective Interventions in Neurodegenerative Diseases of the Striatum
TLDR
The adenosine A2A receptor antagonist SCH 58261 has neuroprot protective effects, although only at low doses, in an excitotoxic rat model of HD, and the inhibition of QA-evoked glutamate outflow seems to be the major mechanism underlying the neuroprotective effects.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 101 REFERENCES
Protective effects of 5-HT1A receptor agonists against neuronal damage demonstrated in vivo and in vitro
TLDR
The result demonstrate neuroprotective potency of the 5-HT1A agonists, urapidil and CM 57493, when applied under hypoxic, excitotoxic and ischemic conditions in vivo and in vitro, respectively.
Limiting Ischemic Injury by Inhibition of Excitatory Amino Acid Release
  • S. Graham, Jun Chen, F. Sharp, R. Simon
  • Biology, Medicine
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 1993
TLDR
Results demonstrate that drugs that inhibit glutamate release in ischemia may be nontoxic and show promise for the treatment of stroke.
Inhibition of ischemia-induced glutamate release in rat striatum by dihydrokinate and an anion channel blocker.
TLDR
These findings support the hypothesis that both cell swelling-induced release of EAAs and reversal of the astrocytic glutamate transporter are contributors to the ischemia-induced increases of extracellular EAAs in the striatum as measured by microdialysis.
Cerestat and other NMDA antagonists in ischemic stroke
  • K. Lees
  • Biology, Psychology
    Neurology
  • 1997
TLDR
Encouraging experience with aptiganel, magnesium, and glycine antagonists has prompted continued clinical trials with these agents, and trials need to be of sufficient size to detect a clinically useful improvement in outcome.
...
1
2
3
4
5
...